|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123385 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-26 17:55:31 |
|
注册时间: Date of Registration: |
2026-04-26 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
维生素D-VDR调控Nrf2通路抑制七氟烷诱导神经元铁死亡的机制及围术期神经保护研究 |
|
Public title: |
Vitamin D-VDR Regulates Nrf2 Pathway to Inhibit Sevoflurane-Induced Neuronal Ferroptosis: Mechanism and Perioperative Neuroprotection |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
维生素D-VDR调控Nrf2通路抑制七氟烷诱导神经元铁死亡的机制及围术期神经保护研究 |
|
Scientific title: |
Vitamin D-VDR Regulates Nrf2 Pathway to Inhibit Sevoflurane-Induced Neuronal Ferroptosis: Mechanism and Perioperative Neuroprotection |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李丽 |
研究负责人: |
李丽 |
|
Applicant: |
Lili |
Study leader: |
Lili |
|
申请注册联系人电话: Applicant telephone: |
+86 87787446 |
研究负责人电话:
Study leader's |
+86 87787446 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xiaoyatoulili0919@163.com |
研究负责人电子邮件: Study leader's E-mail: |
xiaoyatoulili0919@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
居民身份证 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
天津市北辰区龙岩道238号 |
研究负责人通讯地址: |
天津市北辰区龙岩道238号 |
|
Applicant address: |
No.238 Longyan Road,Beichen District,Tianjin |
Study leader's address: |
Longyan Road,Beichen District,Tianjin |
|
申请注册联系人邮政编码: Applicant postcode: |
300100 |
研究负责人邮政编码: Study leader's postcode: |
300100 |
|
申请人所在单位: |
天津市儿童医院 |
||
|
Applicant's institution: |
Tianjin Children's Hospital |
||
|
研究负责人所在单位: |
天津市儿童医院 |
||
|
Affiliation of the Leader: |
Tianjin Children's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-TYXWKY-001 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
天津市儿童医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Tianjin Children's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-29 00:00:00 | ||
|
伦理委员会联系人: |
翟嘉 |
||
|
Contact Name of the ethic committee: |
Zhaijia |
||
|
伦理委员会联系地址: |
天津市北辰区龙岩道238号 |
||
|
Contact Address of the ethic committee: |
Longyan Road,Beichen District,Tianjin |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 87787861 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
天津市儿童医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Tianjin Children's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
天津市北辰区龙岩道238号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Longyan Road,Beichen District,Tianjin |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
天津医科大学总医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Tianjin Medical University General Hospital |
||||||||||||||||||||||
|
研究疾病: |
术后谵妄 |
||||||||||||||||||||||
|
Target disease: |
postoperativedelirium |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
本研究旨在明确术前维生素D水平作为儿童POD预测指标的敏感性,并通过基础实验探索其潜在的作用机制,即维生素D与维生素D受体(VDR)结合后,如何调控Nrf2通路并抑制铁死亡,减少海马神经元损伤,从而为小儿术后谵妄的防治提供新的理论依据和干预靶点。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to determine the sensitivity of preoperative vitamin D levels as a predictor for pediatric postoperative delirium (POD) and to investigate its potential mechanisms through foundational experiments, specifically how vitamin D binds to the vitamin D receptor (VDR), regulates the Nrf2 pathway, and inhibits ferroptosis, which helps reduce hippocampal neuronal damage. This offers new theoretical foundations and intervention targets for preventing and treating postoperative delirium in children. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
性别不限,年龄 3-6 岁,择期全麻下行腹腔镜手术,美国麻醉医师协会(ASA)分级Ⅰ-Ⅱ级,患儿及监护人均对研究知请,并已签署同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
No gender restrictions; children aged 3–6 years; scheduled laparoscopic surgery under general anaesthesia; American Society of Anesthesiologists (ASA) classification I–II; both the child and their guardian are fully informed about the study and have signed the consent form. |
||||||||||||||||||||||
|
排除标准: |
1.患儿经历过全麻手术 2.近两周出现上呼吸道感染、有哮喘病史等呼吸系统疾病者 3.先天性心脏病、先天性发育不良等心功能不全者 4.严重肝肾疾病者 5.体重指数(BMI)>=30者 6.患儿存在智力障碍、发育迟缓及精神疾病者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.The child has undergone general anesthesia surgery 2.Those with respiratory diseases such as upper respiratory tract infection and a history of asthma in the past two weeks 3.Those with cardiac insufficiency such as congenital heart disease and congenital dysplasia 4.Those with severe liver and kidney diseases 5.Those with a body mass index (BMI) >= 30 6.Children with dysgnosia, developmental delay, and mental illnesses |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-01 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-09-08 00:00:00 至 To 2026-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
20260630 国家人口健康科学数据中心 https://www.ncmi.cn/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
20260630 National Public Health Center https://www.ncmi.cn/ |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
标准化采集流程:由经过统一培训的病房护士或医生,按照标准操作程序(SOP)进行采集、处理和临时存储。 数据库提取:临床病例信息(如诊断、实验室结果、影像报告)从医院的电子病历系统(EMR) 和医院信息系统(HIS) 中提取,并经过去标识化处理。 生物样本: 销毁:研究结束后,剩余的生物样本通常将在伦理委员会监督下进行物理销毁(如高压灭菌焚烧)。 数据: 长期保存:所有电子数据在去标识化后,将永久保存于医院的加密服务器或国家级数据库平台(如国家人口健康科学数据中心),用于可能的审计或未来研究。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Standardized Collection Process: Samples are collected, processed, and temporarily stored by ward nurses or doctors who have undergone standardized training, following standard operating procedures (SOP). Database Extraction: Clinical case information (such as diagnosis, laboratory results, imaging reports) is extracted from the hospital's electronic medical record system (EMR) and hospital information system (HIS), and de-identified. Biological Samples: Destruction: After the study concludes, remaining biological samples are usually destroyed (e.g., high-pressure sterilization or incineration) under the supervision of an ethics committee. Data: Long-term Storage: All electronic data, after being de-identified, will be permanently stored on the hospital's encrypted servers or national database platforms (such as the National Population Health Science Data Center) for possible audits or future research. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |